Biobanks, an under used resource Mark Divers Karolinska Institutet Biobank och BBMRI.se Vinnova VR workshop, Stockholm, juni 2012 Forskningsinfrastruktur för industriella innovationer But biobanking is hot! Big interest >$1B technology spend per year Big population studies appeared Hunt, decode, UK Biobank, LifeGene, LifeLines, Kadoorie Big analysis transformation Genetic and protein technologies Big discussion Many hopes, many fears 2 Growing impact on medical research Huge public health opportunity 1
What is a biobank? Organiserad collection of biological samples Often human Archived long term Frozen: 20, 80, 190 C Searchable & accessible Samples and data Used for research, development and healthcare Described as gold mine! Regulated by law MD1 Biobank landscape of Sweden 579 Biobanks 2
Biobank landscape of Sweden for healthcare Tissue 114 M sampels Cells 28, 7 M Blood/plasma 4530000 Serum 2200000 DNA/RNA 69000 Bone 110000 Others 106000 Biobank landscape of Sweden for research Blood/Plasma 4,2 M Serum 2,3 M DNA/RNA 572000 Tissue 51000 Urin 230000 Salivia 112000 Other 47000 3
The biobanks of KI and BBMRI.se are a rich source of samples: 150 studies Population cohorts TwinGene, LifeGene, EpiHealth Karma, Stockhom 2 Disease based studies Cancer CV Neurological Inflammatory Immunological Quality registers A good climate for biobank-based research in Sweden Well characterised population personal number system systematic registries Track record Eg Swedish Twin Registry TwinGene Large population cohorts emerged 2009 LifeGene, EpiHealth Long term research impact Public support 4
But challenges too Fragmentation Organisational Logistic Economic Complex ethico legal landscape EU BBMRI initiative: our chance to create biobanks of the future Technology: test and apply the best! Network: connect modern biobanks! Vision: 300 biobanks throughout EU Harmonise: evolve common standards! Add big public health value! Swedish Science Research Council and KI fund BBMRI.se for 5 years 5
large-scale Swedish Biobanking (SSB); a service for big national studies Some biobank accounts May 2012 Total KIBB BBMRI.se # studies 150 140 10 # samples 2 634 210 584 578 2 049 632 # donors 233 950 153 201 80 749 # DNA samples 197 519 138 963 58 556 # withdrawals >225 000 >175 000 >50 000 6
Creating a BBMRI.se national network Progressive build up in medical universities Goteborg node launch Jan 2012 1st project: Scapis Malmö node Co ordinated: Sample format Data format Processes Equipment & consumables Access and use launch 1Q2012 1st projects: EpiHealth, MKC, MFM Linköping, Umeå, Uppsala to come Linköping launch 1H2013? Projects identified Starting co ordination with healthcare biobanking 13 Unifying Swedish biobanks further University + Healthcare biobanks National common infrastructure VR SKL declaration Regional partnerships, eg Uppsala biobank Göteborg Region Skåne KI SLL 7
Why are we biobanking?... Study publications to advance medical research! Combine with modern bio analysis Systematic Statistical power Huge potential for public health GALLSTEN 4 PAIN 2 BAMSE 8 SCALE 15 Ekonomiskt beteende 2 TwinGene & Euroclot 13 HARMONY & SATSA 12 KTS 1 CAPS 40 Totalt 97 Emerging highlights Multiple Sclerosis TwinGene Broad Influenza Like Illnesses Prostate Cancer What is the value of biobanking?... Multiple Sclerosis research gives a great example* ~17K MS cases in Sweden Many represented in our biobank New therapy, Tysabri Monoclonal antibody Very effective, very expensive Serious side effects in some (polyoma viral cross reacton) Screen MS biobank for polyoma virus Save big drug cost (200KKr/patient/yr) Save some lives, improve others Match a good drug to the right patients *T Olsson et al http://www.pharmatimes.com/article/12 01 23/New_Tysabri_label_to_personalise_treatment.aspx 16 8
Biobanking adds big value 2012-01-03 Mark Divers Clinical practice Better screening, diagnosis and treatment match Health economy Better public health for lower cost eg HPV, MS Drug development Matching patients to treatments eg MS, HIV, HPV Ethical credibility Increased trust and support eg HPV Biobanks for industrial innovation? Discovery & Development Pharmaceuticals Biomarkers Patient subtyping Metabolites Safety profiling Diagnostics 9
The BBMRI Crew Joakim Dillner Jan-Eric Litton Mats Hansson Göran Hallmans Ulf Landegren Joakim Galli Lars-Olof Hansson Joyce Carlsson Lisen Arnheim-Dahlström Sofie Pettersson Martin Fransson Loreana Norlin Maria Anderberg The LifeGene Crew including Jens Mattsson Kicki Kjaergaard Mats Thurman Camilla Björk Thomas Bergman Acknowledgements Lab Operations Carita Rask Jaspal Singh Cecilia Agardh Peter Arnerlöv Anci Carman Pia Hillelson Camilla Lagerberg Vian Osman Amina Said Anette Selander Johanna Smith Siwonne Andersson Emma Ridell William Day Valentina Novak Karin Lindqvist The Biobank Crew Biobank IT Eva Büren Staffan Bergh Jonas Birgersson Ulrika Bohlin Jesper Lind Johan Stenninger José Tapia Anni Åsberg Niclas Ahlin Biobank Development Gunnel Tybring Customer Relations Tove Rylander-Rudqvist Cecilia Björkdahl Quality Anette Petersson Mirja Larsson Project coordination Anders Brinne Others @ KI Henrik Grönberg Per Hall Nancy Pedersen Rune Franson Per Spångeus More info http://ki.se/kibiobank www.bbmri.se www.lifegene.se 19 10